Christopher Raymond
Stock Analyst at Piper Sandler
(3.30)
# 1,024
Out of 5,055 analysts
138
Total ratings
50.44%
Success rate
1.6%
Average return
Main Sectors:
Stocks Rated by Christopher Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Maintains: Neutral | $9 → $10 | $5.86 | +70.65% | 10 | Nov 4, 2025 | |
| TSHA Taysha Gene Therapies | Initiates: Strong Buy | $13 | $4.13 | +214.77% | 3 | Oct 21, 2025 | |
| MGTX MeiraGTx Holdings | Initiates: Strong Buy | $29 | $8.18 | +254.52% | 2 | Oct 21, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $231 → $284 | $232.36 | +22.22% | 13 | Oct 10, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $42 → $70 | $110.39 | -36.59% | 2 | Jul 23, 2025 | |
| BIIB Biogen | Maintains: Neutral | $135 → $115 | $167.55 | -31.36% | 21 | Apr 29, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Overweight | $8 → $9 | $1.38 | +552.17% | 6 | Mar 6, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $122 → $126 | $54.73 | +130.22% | 15 | Feb 20, 2025 | |
| QTTB Q32 Bio | Downgrades: Neutral | $20 → $4 | $2.16 | +85.19% | 3 | Feb 11, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $533 | $437.15 | +21.93% | 8 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1,195 → $1,013 | $693.50 | +46.07% | 7 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $33.08 | +323.22% | 5 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $78.04 | -7.74% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $3 → $13 | $2.52 | +415.87% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $75 | $5.70 | +1,216.94% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $76 | $8.30 | +815.66% | 7 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 | $0.83 | +1,108.31% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $15.73 | +109.79% | 1 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 | $33.54 | -34.41% | 1 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2 → $4 | $1.67 | +139.52% | 3 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $293 → $288 | $336.74 | -14.47% | 16 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $41 | $43.65 | -6.07% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $42.40 | -33.96% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $96.50 | -58.55% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $4.24 | +2,022.64% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $96 | $2.05 | +4,582.93% | 2 | Mar 13, 2020 |
Ardelyx
Nov 4, 2025
Maintains: Neutral
Price Target: $9 → $10
Current: $5.86
Upside: +70.65%
Taysha Gene Therapies
Oct 21, 2025
Initiates: Strong Buy
Price Target: $13
Current: $4.13
Upside: +214.77%
MeiraGTx Holdings
Oct 21, 2025
Initiates: Strong Buy
Price Target: $29
Current: $8.18
Upside: +254.52%
AbbVie
Oct 10, 2025
Maintains: Overweight
Price Target: $231 → $284
Current: $232.36
Upside: +22.22%
ABIVAX Société Anonyme
Jul 23, 2025
Maintains: Overweight
Price Target: $42 → $70
Current: $110.39
Upside: -36.59%
Biogen
Apr 29, 2025
Maintains: Neutral
Price Target: $135 → $115
Current: $167.55
Upside: -31.36%
ALX Oncology Holdings
Mar 6, 2025
Maintains: Overweight
Price Target: $8 → $9
Current: $1.38
Upside: +552.17%
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Overweight
Price Target: $122 → $126
Current: $54.73
Upside: +130.22%
Q32 Bio
Feb 11, 2025
Downgrades: Neutral
Price Target: $20 → $4
Current: $2.16
Upside: +85.19%
Vertex Pharmaceuticals
Jan 27, 2025
Maintains: Overweight
Price Target: $535 → $533
Current: $437.15
Upside: +21.93%
Jan 27, 2025
Maintains: Overweight
Price Target: $1,195 → $1,013
Current: $693.50
Upside: +46.07%
Jan 13, 2025
Maintains: Overweight
Price Target: $135 → $140
Current: $33.08
Upside: +323.22%
Jan 10, 2025
Initiates: Overweight
Price Target: $72
Current: $78.04
Upside: -7.74%
Nov 18, 2024
Upgrades: Overweight
Price Target: $3 → $13
Current: $2.52
Upside: +415.87%
Nov 6, 2024
Maintains: Overweight
Price Target: $60 → $75
Current: $5.70
Upside: +1,216.94%
Sep 23, 2024
Maintains: Overweight
Price Target: $66 → $76
Current: $8.30
Upside: +815.66%
Sep 3, 2024
Maintains: Overweight
Price Target: $10
Current: $0.83
Upside: +1,108.31%
Aug 15, 2024
Initiates: Overweight
Price Target: $33
Current: $15.73
Upside: +109.79%
Jun 12, 2023
Maintains: Overweight
Price Target: $22
Current: $33.54
Upside: -34.41%
May 31, 2023
Upgrades: Overweight
Price Target: $2 → $4
Current: $1.67
Upside: +139.52%
Apr 28, 2023
Maintains: Overweight
Price Target: $293 → $288
Current: $336.74
Upside: -14.47%
Feb 3, 2023
Initiates: Overweight
Price Target: $41
Current: $43.65
Upside: -6.07%
Jul 26, 2022
Initiates: Overweight
Price Target: $28
Current: $42.40
Upside: -33.96%
Aug 23, 2021
Initiates: Overweight
Price Target: $40
Current: $96.50
Upside: -58.55%
Jul 12, 2021
Initiates: Neutral
Price Target: $90
Current: $4.24
Upside: +2,022.64%
Mar 13, 2020
Downgrades: Neutral
Price Target: $96
Current: $2.05
Upside: +4,582.93%